NEW YORK (GenomeWeb) — Finnish diagnostics firm Mobidiag said today that it has signed three distribution deals for its Amplidiag and Novodiag lines of infectious disease and antibiotic resistance testing products in Europe and the Middle East.
According to Mobidiag, it has granted the exclusive distribution rights for the Amplidiag and Novodiag products to Helix2 in Greece and Interlab Interautomatika UAB in Latvia and Lithuania. It has also signed an exclusive distribution deal for the Novodiag line in Kuwait with Ibn Rushd Medical & Scientific Equipment.
The agreements have two-year terms. Additional details were not disclosed.
"We are delighted to have extended our commercial footprint into new international territories including our first agreement in the Middle East," Mobidiag CEO Tuomas Tenkanen said in a statement. "Mobidiag continues to see demand grow for the Amplidiag and Novodiag solutions and we are in discussions with several distribution partners in a range of international markets."
Earlier this month, Mobidiag announced the completion of a $11.3 million equity investment from Autobio Diagnostics, the proceeds of which will be used in part to continue its commercial expansion.